trending Market Intelligence /marketintelligence/en/news-insights/trending/gawQzUy1_jzIGghjzdgvkg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Actinium drug shows reduction in leukemia in initial phase 2 data

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Actinium drug shows reduction in leukemia in initial phase 2 data

Actinium Pharmaceuticals Inc. reported positive preliminary data from the phase 2 trial of Actimab-A to treat patients with acute myeloid leukemia.

The ongoing study is being conducted in 13 patients with newly diagnosed acute myeloid leukemia, or AML, aged 60 and above and not able to tolerate induction chemotherapy.

According to the the initial data presented at the 59th American Society of Hematology Annual Meeting, 69% of patients saw a reduction in their disease. The patients also had a median reduction in bone marrow blasts of 98%.

There were minimal extramedullary toxicities recorded, with only pneumonia and septic shock observed in more than one patient in the trial. There was no evidence of veno-occlusive disease of any grade in any of the patients.

Veno-occlusive disease is a potentially fatal complication of the liver that can prevent a patient from having a stem cell transplant.